Literature DB >> 2987295

The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium.

A Couvineau, M Laburthe.   

Abstract

To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate). Sodium dodecyl sulfate-polyacrylamide gel autoradiographic studies of affinity labeled membranes revealed three major bands corresponding to [125I]VIP-protein complexes of 66,000, 33,000, and 16,000 mol wt. Labeling of the 66,000 and 33,000 mol wt complexes was specific, since it was abolished by VIP, while labeling of the 16,000 mol wt complex was not. Densitometric scanning of autoradiographs indicated that labeling of the 66,000 mol wt complex was inhibited by low VIP concentrations in the 10(-10)-10(-8) M range, but was unaffected by glucagon or octa-cholecystokinin. It was also reduced by VIP-(2-28), with a potency 1/100th that of VIP, and by GTP in the concentration range of 10(-7)-10(-3) M. The 33,000 mol wt complex behaved similarly to the 66,000 mol wt complex with respect to specificity and GTP sensitivity, but differed in one major feature, its affinity for VIP. Its labeling was inhibited by native VIP concentrations in the 10(-9)-10(-7) M range. Assuming one molecule of [125I]VIP bound per molecule of protein, two proteins of 63,000 and 30,000 mol wt were identified as VIP-binding sites. The 63,000 mol wt protein had the properties expected for the VIP receptor coupled to adenylate cyclase in human colon, while the 30,000 mol wt protein was a low affinity binding site. Treatment of human colonic membranes with the sulfhydryl reducing agent dithiothreitol before [125I]VIP binding strongly reduced the labeling of the two proteins. This finding does not support the hypothesis that the low affinity 30,000 mol wt binding site may be a monomer of the high affinity binding site.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987295     DOI: 10.1210/jcem-61-1-50

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  VIP receptors and control of short circuit current in the human intestinal clonal cell line Cl.19A.

Authors:  C Rouyer-Fessard; C Augeron; E Grasset; J J Maoret; C L Laboisse; M Laburthe
Journal:  Experientia       Date:  1989-12-01

2.  The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y1 receptor.

Authors:  N D Holliday; H M Cox
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

3.  The vasoactive intestinal peptide receptor on intact human colonic adenocarcinoma cells (HT29-D4). Evidence for its glycoprotein nature.

Authors:  A el Battari; J Luis; J M Martin; J Fantini; J M Muller; J Marvaldi; J Pichon
Journal:  Biochem J       Date:  1987-02-15       Impact factor: 3.857

4.  PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.

Authors:  Mathew L Thakur; Mohan R Aruva; Jean Gariepy; Paul Acton; Satish Rattan; Shyam Prasad; Eric Wickstrom; Abass Alavi
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

5.  PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.

Authors:  Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Satish Rattan; Chirag Patel; Christopher Kim; Peter A McCue; Eric Wickstrom; Mathew L Thakur
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

6.  Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.

Authors:  Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Chirag A Patel; Satish Rattan; Gregory Cesarone; Eric Wickstrom; Mathew L Thakur
Journal:  Regul Pept       Date:  2007-07-06

7.  Ropivacaine and lidocaine inhibit proliferation of non-transformed cultured adult human fibroblasts, endothelial cells and keratinocytes.

Authors:  T Martinsson; A Haegerstrand; C J Dalsgaard
Journal:  Agents Actions       Date:  1993-09

8.  Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.

Authors:  A Couvineau; M Rousset; M Laburthe
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.